0:00
/
Transcript

Why Costco Is the Most Challenged Big Retailer at 47x Earnings

Amazon, Walmart, and Costco are converging on the same customer — and the valuations tell the story

Mike, Hunt, and Jason work through a revised oil thesis, the converging big-retail battle between Amazon, Walmart, and Costco, a hyperscaler preview, and the most-favored-nations finish line in pharma.

The Cashflow Memo

4 27 26 20 Pager
560KB ∙ PDF file
Download
Download

Key Takeaways

  • Hunt revised his oil thesis: the Strait of Hormuz impasse with Iran now looks structural after the US rejected Iran’s offer of a 5-year enrichment pause, pushing near-month oil from a ~$90 anchor toward a $110–$120 range with downstream pressure on natural gas as Permian associated gas keeps Waha hub pricing in negative territory.

  • Big retail is converging on the same customer: Walmart’s PE ran from low-20s to mid-40s, Costco trades at 47x with a $440B market cap and no debt, and Amazon’s 12-month PE has fallen below Walmart’s for the first time despite running zero-margin retail monetized through advertising and a logistics network now larger than UPS.

  • The hosts singled out Costco as the most challenged of the three on valuation alone — 47x for a retailer with an unclear growth runway leaves no margin of safety, while Amazon retail looks structurally underpriced if AWS is roughly two-thirds of the $2.8T EV (implying ~$1.2T for everything else, vs. Walmart’s $1T enterprise value).

  • Defense tech is the next disruption beat: $30,000 drones have effectively kept US destroyers offshore in the Gulf, F-35-style cost-plus contracting is broken, and Palantir-style product-first defense companies (Palantir was added this week to the Netflix page in the memo) are the model — Hunt is hunting for a drone-company addition next.

  • Healthcare update: the White House finalized Most Favored Nations contracts with all 17 top pharma companies (Regeneron last), Lilly is on an acquisition spree, and Teva bought a biotech with no approved drugs in market — Jason stays constructive on generics manufacturers as the structural winners of the looming patent-cliff wave.

Show Notes

[00:00:18] Disclaimer Standard informational disclaimer.

[00:00:27] Exhibit C: Oil and the Hormuz Impasse Hunt walks through a meaningful change in his oil supply/demand view — the US-Iran embargo now looks structural after Iran’s enrichment offer was rejected. Near-month oil targets shift toward $110–$120.

[00:05:38] Exhibit B: Gas and the Permian Problem Stronger oil pulls more associated gas out of the Permian, pushing Waha hub pricing into negative territory and supporting a bearish gas outlook into 2027.

[00:09:00] Exhibit A: Federal Cashflow and Defense Spending Healthcare cost flattening, Doge aftereffects, and why the real defense fight is about efficiency, not topline.

[00:11:58] Defense Tech Disruption Jason and Mike on Palantir’s product-first model, the F-35 lesson, and why the prime-contractor lobby is the main obstacle to better procurement.

[00:14:14] New Memo Additions: Palantir and Micron Hunt adds Palantir to the Netflix page and Micron to the telecom page in this weekend’s 4/27 draft.

[00:15:35] Big Retail: Amazon vs Walmart vs Costco Walmart and Costco trade at mid-40s PE; Amazon’s PE has slipped below Walmart’s for the first time despite hidden value in retail and logistics.

[00:23:04] Why Costco Looks Most Challenged At 47x with no obvious growth runway, Costco has the thinnest margin of safety of the three.

[00:25:43] Hyperscaler Preview AWS is roughly 50% larger than Azure, implying AWS is ~two-thirds of Amazon’s EV and leaving the retail + logistics piece around $1.2T — vs. Walmart’s $1T.

[00:28:33] OpenAI, SoftBank, Oracle WSJ flags OpenAI missing 2025 budget targets, with knock-on effects to SoftBank, Oracle, and AMD — Jason notes the spending plan hasn’t actually changed.

[00:29:33] Pharma: Most Favored Nations Complete White House finalized MFN contracts with all 17 top pharma companies, Regeneron last. FDA is exploring real-time trial-data review.

[00:31:03] M&A: Lilly Spree, Teva Strategy Shift Lilly keeps acquiring; Teva buys a biotech with no approved drugs — a possible drift away from generics at the worst time, given the patent-cliff tailwind ahead.

[00:32:30] Coming Attractions Hyperscaler deep dive, Anthropic, a drone-company memo addition, and Circle on the Mastercard page.

Get the Cashflow Memo at telltales.us and subscribe for new episodes every Wednesday.

Cashtags

$AMZN $WMT $COST $PLTR $MU $MSFT $GOOG $ORCL $AAPL $NVDA $LLY $REGN $TEVA $SPOT $TMUS $VZ $T $UPS $MA $AMD


This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

Discussion about this video

User's avatar

Ready for more?